sexta-feira, 6 de novembro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 23, 2025

Communiqué de presse : Le Dupixent de Sanofi et Regeneron approuvé au Japon pour les enfants de 6 à 11 ans atteints d’asthme bronchique

View original at globenewswire.com
Communiqué de presse : Le Dupixent de Sanofi et Regeneron approuvé au Japon pour les enfants de 6 à 11 ans atteints d’asthme bronchique Le Dupixent de Sanofi et Regeneron approuvé au Japon pour les enfants de 6 à 11 ans atteints d’asthme bronchique Approbation basée sur le programme mondial de phase 3 chez les enfants…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Dupilumab has been studied in more than 60 clinical trials involving more than 10,000 patients with various chronic diseases partly due to type 2 inflammation

    80% confidence

  • Uncontrolled asthma in young children can have potentially lasting impacts such as reduced lung growth and persistent airway obstruction if not treated early

    80% confidence

  • Dupixent is the first and only biologic medicine to demonstrate improvement in lung function in this group of young patients in a randomized phase 3 study

    80% confidence

  • Dupixent is a fully human monoclonal antibody that inhibits IL-4 and IL-13 signaling pathways and is not an immunosuppressant

    80% confidence

  • Dupixent has received regulatory approvals in more than 60 countries for one or more indications

    80% confidence

  • More than 1.3 million patients are treated with Dupixent worldwide

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,996
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,996 factos verificados com a fonte5,552 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Communiqué de presse : Le Dupixent de Sanofi et Regeneron approuvé au Japon pour les enfants de 6 à 11 ans atteints d’asthme bronchique — Source | Via News | pt.VIA.NEWS